Clinical trials: Dizziness
Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure
Positive Care Effect of the Digital Health Assistant ADELE Blood Pressure for Hypertension Patients
High blood pressure (hypertension) can cause damage to vital organs such as the heart, kidneys, eyes, brain and blood vessels. The risk of developing high blood pressure increases with age.
- Conditions
- Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure, Hypertensive Heart Disease Without (Congestive) Heart Failure, Other Secondary Hypertension
- Trial name
- A0007 (NCT06663280)
- Testing
- Digital health assistant ADELE
- Where
- 2 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Alma Phil Gmbh
Dizziness, Nausea
Efficacy of a Non-invasive Vestibular System Masking for Improving Outcomes Following Acute Unilateral Vestibulopathy
Vestibular disorders are among the most common causes of disability in society and affect over 50% of the population over the age of 65 and a significant percentage of the younger population.
- Trial name
- NCT04226976
- Testing
- Otoband
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Otolith Labs
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Meniere's Disease
OTO-104 for Meniere's Disease
The purpose of this study is to evaluate the safety of OTO-104 in subjects with unilateral Meniere's disease. The effectiveness of OTO-104 to reduce the symptoms of Meniere's disease will also be evaluated.
- Trial name
- NCT01084525
- Testing
- OTO-104 (steroid) 3 mg, OTO-104 (steroid) 12 mg
- Where
- 15 sites in United States
- Volunteers
- 44 people
- Sponsor
- Otonomy, Inc.
Meniere's Disease, Ménière's Disease
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.
- Trial name
- NCT06859788
- Testing
- Ebselen
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Acute Vertigo
Effect of V0251 in Acute Vertigo
Assessment of efficacy and tolerance of a new anti-dizziness drug in acute vertigo.
- Trial name
- NCT01583738
- Testing
- V0251
- Where
- 40 sites in Czechia, France and 3 more
- Volunteers
- 132 people
- Sponsor
- Pierre Fabre Medicament
Orthostatic Hypotension, Parkinson's Disease
A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease
This is a study to evaluate the effects of an investigational drug, Droxidopa, in participants with neurogenic orthostatic hypotension (NOH), associated with Parkinson's disease.
- Trial name
- 306A/306B (NCT01176240)
- Testing
- Droxidopa
- Where
- 60 sites in United States
- Volunteers
- 225 people
- Sponsor
- Chelsea Therapeutics
Vestibular Function Tests, Dizziness
Efficacy of a Transcranial Vibrating System for Minimizing Dizziness During Caloric Testing
Vestibular disorders are among the most common causes of disability in society. Vestibular dysfunction affects over one third of the population over the age of 40 and a significant percentage of the younger population.
- Trial name
- NCT03618199
- Testing
- Efficacy of transcranial vibrating system on mitigating dizziness and nausea during caloric testing
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Otolith Labs
Symptomatic Neurogenic Orthostatic Hypotension
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.
- Trial name
- OAK (NCT04095793)
- Testing
- ampreloxetine
- Where
- 55 sites in United States, Australia and 16 more
- Volunteers
- 110 people
- Sponsor
- Theravance Biopharma
Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent
Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study
This is a prospective, non-randomized, multi-center, real-world post-market study to collect and evaluate data regarding the performance of the enhanced atrial fibrillation detection algorithm of the Assert-IQTM Implantable…
- Conditions
- Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent, Cardiac Arrhythmia, Ablation
- Trial name
- Assert-IQ (NCT06172699)
- Testing
- Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device
- Where
- 11 sites in United States
- Volunteers
- 151 people
- Sponsor
- Abbott Medical Devices
Meniere's Disease
Study of OTO-104 in Subjects With Unilateral Meniere's Disease
The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.
- Trial name
- AVERTS-1 (NCT02612337)
- Testing
- OTO-104
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- Otonomy, Inc.
Lymphoma
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter…
- Trial name
- NCT03098589
- Testing
- Revlimid
- Where
- Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Vestibular Migraine, Migraine Associated Vertigo
SENSE-VM: Safety and Effectiveness of a Novel Medical Device for Symptom Ease in Vestibular Migraines
The goal of this virtual clinical trial is to compare the effectiveness of two study devices in providing temporary relief to adults aged 18-75 who suffer from symptoms of chronic Vestibular Migraines (VM), also known as Migraine…
- Trial name
- NCT06267924
- Testing
- Otoband Experimental
- Where
- United States
- Volunteers
- 322 people
- Sponsor
- Otolith Labs
Meniere's Disease
Study to Evaluate SPI-1005 in Adults With Meniere's Disease
This study will evaluate the safety and efficacy of three dose levels of SPI-1005 compared to placebo on vertigo, tinnitus and sensorineural hearing loss in 40 adults with Meniere's disease.
- Trial name
- NCT02603081
- Testing
- SPI-1005
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Brain Concussion, Vestibular Disorder
Portable Mixed Reality-based Platform for Assessment of Progress in Multisensory Rehabilitation Strategies Post-TBI
The goal of this comparative pilot study is to provide evidence that Praxis, a portable testbed with low-cost wearable sensors and a mixed reality environment, can deliver effective multisensory rehabilitation exercises with…
- Conditions
- Brain Concussion, Vestibular Disorder, Cognition Disorder, Mild Traumatic Brain Injury
- Trial name
- Praxis (NCT06314464)
- Testing
- Praxis, Supervised cardiovascular exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BlueHalo
Pulmonary Arterial Hypertension
Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
This was a non-confirmatory, randomized, placebo controlled, subject and investigator blinded study of QCC374 in PAH subjects. The study was planned to have 2 Parts: Part 1, an initial safety cohort with a 0.03 mg bid starting…
- Trial name
- NCT02927366
- Testing
- QCC374
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Dizziness, Vertigo
Quantification of the Effect of the OtoBand on Objective Measures of Vertigo and Dizziness
Vestibular disorders are among the most common causes of disability in society and affect over 50% of the population over the age of 65 and a significant percentage of the younger population.
- Conditions
- Dizziness, Vertigo, Vestibular Migraine, Vestibular Neuritis
- Trial name
- NCT05157399
- Testing
- Otoband
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Otolith Labs
Pulmonary Arterial Hypertension
Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients
This is a long-term open-label safety extension to the Phase 2a study of inhaled QCC374 in adult patients with PAH. This study provides the patients who completed the QCC374X2201 study with the option to continue receiving…
- Trial name
- NCT02939599
- Testing
- QCC374
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 5 people
- Sponsor
- Novartis Pharmaceuticals
Arrhythmias, Cardiac, Palpitation
Ambulatory Leadless Electrocardiogram Recorder Trial Feasibility
The goal of this study is to compare the heart signals that are received by a new heart monitoring device called the HeartWatch to heart signals that are recorded by existing monitors used in cardiology clinics today.
- Conditions
- Arrhythmias, Cardiac, Palpitation, Syncope, Light Headedness
- Trial name
- ALERT (NCT05821465)
- Testing
- HeartWatch
- Where
- Canada
- Volunteers
- 144 people
- Sponsor
- HelpWear Inc.